Mesenchymal Stem Cell Therapy for Heart Failure

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for progressive heart failure, particularly in subjects with micro-vascular disease and/or macro-vascular disease, are ineffective in preventing or treating the condition, leading to high rates of cardiac death and non-fatal myocardial infarction or stroke.

Innovation Solution

Administering a composition comprising mesenchymal lineage precursor or stem cells, which are isolated from bone mononuclear cells using anti-STRO-3 antibodies, to subjects with micro-vascular disease and/or macro-vascular disease, including those with myocardial ischemia and/or diabetes, to induce new blood vessel formation and secrete protective factors for the myocardium.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for progressive heart failure in subjects with micro-vascular disease and/or macro-vascular disease, then treatment complexity remains low, but treatment effectiveness is insufficient leading to high rates of cardiac death and non-fatal myocardial infarction or stroke

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidtreatment complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses mesenchymal lineage precursor or stem cells as an intermediary therapeutic agent to treat progressive heart failure. These cells are administered to subjects with micro-vascular disease and/or macro-vascular disease to reduce the risk of cardiac death, non-fatal myocardial infarction, and stroke. The cells act as a mediator between the subject's existing condition and the desired therapeutic outcome, providing a novel treatment mechanism that goes beyond conventional therapies.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If cell therapy is administered to all heart failure patients, then potential benefits may be achieved, but treatment effectiveness is reduced due to lack of targeting at high-risk subjects

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidpatient selection adaptability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies local quality by targeting cell therapy specifically to high-risk heart failure patients based on their micro-vascular disease status, macro-vascular disease status, and other risk factors. Rather than treating all heart failure patients uniformly, the treatment is adapted to the specific needs and risk profiles of individual patients, concentrating therapeutic resources on those who will benefit most.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent employs preliminary action by identifying and selecting high-risk patients before administering cell therapy. The method includes assessing patients for micro-vascular disease, macro-vascular disease, and other risk factors in advance of treatment, allowing the therapy to be targeted to those who will benefit most before the actual cell administration occurs.

Inventive Principle:

Principle #10Preliminary action

3Reliability

If high-risk patients are identified and treated with cell therapy, then treatment effectiveness increases, but assessment complexity increases due to multiple risk factor evaluations

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidrisk assessment difficulty

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent segments the risk assessment process into distinct components: micro-vascular disease assessment, macro-vascular disease assessment, and other risk factor evaluations. This segmentation allows for systematic identification of high-risk patients through multiple independent assessments, making the overall evaluation process more manageable and structured.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method significantly reduces the risk of cardiac death, non-fatal myocardial infarction, and stroke by inhibiting the progression of heart failure and reducing the incidence of ischemic events, particularly in patients with elevated CRP levels and Class II heart failure, thereby improving patient outcomes.

Implementation Method 1

administering a composition comprising mesenchymal lineage precursor or stem cells, which are isolated from bone mononuclear cells using anti-STRO-3 antibodies, to subjects with micro-vascular disease and/or macro-vascular disease, including those with myocardial ischemia and/or diabetes, to induce new blood vessel formation and secrete protective factors for the myocardium

Methodology Applied

Scientific EffectAngiogenesis:

Implementation Method 2

isolated from bone mononuclear cells using anti-STRO-3 antibodies

Methodology Applied

Scientific EffectAntibody-antigen binding:

Data Source

PatentUS20250090589A1Method of treating progressive heart failure in subjects at high risk of poor outcomes

Publication Date: 2025.03.20 MESOBLAST INTERNATIONAL SARL

AI summary

The present disclosure relates to methods for treating and/or preventing progressive heart failure in subjects at high risk of poor outcomes. Such methods may be used for treating or preventing progressive heart failure in subjects with micro-vascular disease and/or macro-vascular disease.